Approximately 10% of patients with amyotrophic lateral sclerosis (ALS) have familial ALS (FALS), and 20% of FALS are caused by mutations of superoxide dismutase type 1 (MTSOD1). The fact that some MTSOD1s that cause FALS have full dismutase activity (e.g. G37R) and others no dismutase activity (e.g. G85R) suggests that MTSOD1 causes FALS due to toxicity of the protein rather than a loss in enzymatic function. Compelling data have demonstrated that motor neuron (MN) degeneration can result from a non-cell autonomous effect of the MTSOD1. In order to clarify the role of astrocytes in FALS, we deleted MTSOD1 in astrocytes of G85R transgenic mice. In contrast to a similar study using G37R mice in whvich astrocyte MTSOD1 loss affected only the late phase of ALS disease, we found that astrocyte MTSOD1 loss in G85R mice delayed disease onset and prolonged the early phase of disease progression, without affecting the late phase. In addition, astrocyte G85R knockdown resulted in decreased microgliosis, decreased SOD1-immunoreactive inclusions and preservation of GLT-1 transporter expression. The differential effects of astrocyte G85R versus G37R knockdown on MN death demonstrate SOD1 mutation-specific effects on ALS pathogenesis; these differences may be a result of the different dismutase activities of the two mutants. The effect of the knockdown of G85R expression in astrocytes on onset as well as disease duration highlights the importance of this cell type in FALS.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that usually causes death within 3-5 years of the onset and has no effective treatment. As in the case with other neurodegenerative diseases, the identification of genes that underlie the inherited syndromes has enhanced our understanding of the sporadic disease. Approximately 20% of familial ALS (FALS) is caused by mutations in superoxide dismutase-1 (SOD1) (reviewed in 1). Of note, recent publications have suggested that abnormalities of SOD1 may play a role in the pathogenesis of sporadic ALS as well as FALS (2, 3) . Although the pathogenesis of FALS remains incompletely understood, studies directed at mutant (MT) SOD1-induced motor neuron (MN) degeneration have clarified certain features of the disease. For example, a number of studies have convincingly shown that MTSOD1 causes FALS because of a toxic gain in function rather than a deficiency of dismutase activity.
One theme that has emerged from investigations of MTSOD1-induced FALS-as well as other neurodegenerative diseases-is that of non-cell autonomous degeneration (4) . Cre/loxP studies from Cleveland and co-workers (5) using G37R MTSOD1 transgenic mice have demonstrated a contribution of different cell types to MTSOD1-induced MN disease (MND). We have carried out similar studies using G85R flox MTSOD1 transgenic mice (6) , which offer several features that complement the investigations of G37R mice: (i) astrocytes have been proposed to be especially important in the pathogenesis of the MND in a previously characterized G85R transgenic mouse because G85R aggregates accumulated very early and prominently in these cells and were associated with an early and progressive decline of the astrocytic GLT-1 transporter (7); (ii) G85R FALS transgenic mice have a very short disease duration compared with the G37R mice-so it is of interest to determine whether disease duration can be prolonged following a knockdown of MTSOD1 in a particular cell type in G85R flox mice to an extent similar to that seen in G37R mice and (iii) G37R MTSOD1 has full SOD1 activity, whereas G85R MTSOD1 has no SOD1 activity [(8) , among others]; therefore, comparing results of Cre/loxP studies involving G37R with G85R may help clarify the effect of the enzyme's activities on non-cell autonomous cell degeneration and MTSOD1-induced disease. For example, if oxidative stress is very much in force in a particular cell type in FALS, then dismutase-active G37R will protect against oxidative damage in this cell type, and therefore, knockdown of MTSOD1 in this cell type in G37R mice would be predicted to have a less ameliorative effect on disease than knockdown of MTSOD1 in this cell type in G85R mice.
In vitro studies have suggested that MTSOD1-expressing astrocytes can decrease MN survival (9, 10) , perhaps because of a downregulation of the GLT-1 glutamate transporter; however, one in vitro study found no decrease in GLT-1 expression in the astrocytes (10) . More recent investigations of mice that carry G37R flox and Cre driven by the glial fibrillary acidic protein (GFAP) transcription control element demonstrated that knockdown of G37R in astrocytes of G37R transgenic mice delayed late disease progression by 60 days and prolonged survival by 48 days, with no effect on disease onset or early disease (11) . Interestingly, this knockdown of G37R in astrocytes led to a delay in microglial cell activation in the spinal cord. The latter finding and the observation that knockdown of G37R in astrocytes had an effect on disease similar to the knockdown in microglial cells (12) suggested that astrocytes may affect disease by determining the timing and infiltration of a pathogenic microglial inflammatory response.
The present study explores the effect of a knockdown of G85R in astrocytes in G85R flox transgenic mice. In contrast to the results with G37R, the knockdown of G85R in astrocytes affected onset and early disease. Our results demonstrate that different mutant SOD1s may have different features that drive the disease; astrocytes can have a substantial effect on MTSOD1-induced disease, including a direct effect on the onset of disease.
RESULTS

Preparation of G85R
flox /GFAP:Cre transgenic mice and quantitation of knockdown in MTSOD1 expression
G85R
flox transgenic mice that have a loxP site flanking a G85R genomic clone have been described (13) . These mice were crossed with GFAP:Cre mice (14) , which express Cre recombinase in GFAP-positive cells, to generate G85R flox /GFAP:Cre double transgenic mice. The expression of Cre recombinase in the G85R flox /GFAP:Cre double transgenic mice is predicted to excise out G85R in GFAP-positive cells, leading to a knockdown of G85R MTSOD1 in these cells, but with continued expression of G85R MTSOD1 in other cell types. Tail DNA of the cross was analyzed by polymerase chain reaction (PCR) to identify mice carrying both transgenes.
A previously published study reported that crossing a Cre-reporter mouse (that activates expression of b-galactosidase Cre-mediated DNA recombination) with the same GFAP:Cre mouse that was used in the present study showed that b-galactosidase activity was only expressed in astrocytes of the spinal cord (11) . To quantitate the degree of knockdown of G85R mRNA and protein in the G85R flox /GFAP:Cre mice used in the present study, we performed real-time reverse transcriptase-qPCR and western immunoblotting on primary cultured astrocytes from G85R flox /GFAP:Cre and G85R flox mice (Fig. 1 ). There was a mean decrease of 79.8 + 6.7% in G85R SOD1 mRNA in G85R flox /GFAP:Cre versus G85R flox mice (P , 0.001) (Fig. 1A) and a mean decrease of 81.3 + 4.9% in G85R SOD1 protein in G85R flox /GFAP:Cre versus G85R flox mice (P ¼ 0.001) (Fig. 1B) . A representative western blot is shown in Figure 1C .
Knockdown of G85R in astrocytes of G85R flox /GFAP:Cre mice delays the onset and early phase of disease Mice were clinically assessed as described previously (12) : the onset of disease was defined as peak weight before a decline; early phase of disease was the period from peak weight until loss of 10% of maximal weight and late phase of disease was the time from 10% loss in weight until death (when a mouse was unable to right itself within 20 s after being put on its back). The mean onset of disease for G85R flox /GFAP:Cre mice was 326.3 + 21.9 days, which was significantly prolonged compared with the onset of 307.7 + 33.2 days for G85R flox mice (P , 0.05) ( Fig. 2A) . In addition, there was a dramatic prolongation in the duration of early disease in G85R flox /GFAP:Cre versus G85R flox mice (33.6 + 7.2 versus 17.5 + 3.7 days, P , 0.001) ( that of G85R flox mice (377.7 + 26.8 versus 340.9 + 33.0 days, P , 0.001) (Fig. 2C ). There was no significant difference in the duration of the late disease, a time when clinical weakness was apparent, in the G85R flox /GFAP:Cre versus the G85R flox mice (17.9 + 4.7 versus 15.7 + 2.9 days, P ¼ 0.09) (Fig. 2E ), indicating that the increased survival was a result of the delayed onset and prolonged early disease and not related to a change in the late disease.
Knockdown of G85R in astrocytes of G85R flox /GFAP:Cre mice delays the pathology and immunohistochemical abnormalities
In order to compare the pathology of G85R flox /GFAP:Cre versus G85R flox mice at similar stages of disease, we examined the lumbar spinal cord anterior horn before onset and at early phase and end stage of disease. As expected, considering that the onset of clinical disease occurred much earlier in the G85R flox mice than G85R flox /GFAP:Cre mice, the typical pathological findings were present earlier in G85R flox mice (Fig. 3A) . Both groups of mice had a progressive decrease in Nissl-stained MNs from the early stage of disease through end stage, when there were few remaining MNs (Fig. 3A) . As expected, MNs were lost much earlier in the G85R flox mice than in the G85R flox /GFAP:Cre mice, i.e. at 340 days, the MN number in the lumbar anterior horn of G85R flox mice fell to 3.7 + 1.8 compared with the MN number in G85R flox /GFAP:Cre mice of 12.3 + 3.7 (Fig. 3B ). There were similar numbers of anti-GFAP antibody-stained astrocytes in the two groups of mice before onset and at end stage of disease; however, the number of astrocytes in G85R flox /GFAP:Cre mice was slightly less than that in G85R flox mice during the early phase of disease (P ¼ 0.002) ( Fig. 3A and C) . Of note, anti-Iba1 antibody-stained microglia/activated macrophages were significantly increased in G85R flox mice compared with G85R flox /GFAP:Cre mice during the times that were evaluated: before onset, at early phase, as well as end stage of disease (P , 0.001) (Fig. 3D) .
Aggregates of MTSOD1 were detected in the lumbar spinal cord of both G85R flox mice and G85R flox /GFAP:Cre mice at end stage (Fig. 4A) . The aggregates were present in cells in the anterior horn that were presumed to be MNs because of their size, but also in other areas, including the white matter. There were markedly fewer SOD1 aggregates at end stage in both the gray and the white matter of G85R flox /GFAP:Cre mice compared with G85R flox mice ( (Fig. 4C) . SOD1 aggregates were also localized in GFAP-positive astrocytes in the case of G85R flox mouse (Fig. 4D) ; however, rare, if any, SOD1 aggregates were detected in astrocytes of G85R flox /GFAP:Cre mice.
Knockdown of G85R in astrocytes of G85R flox /GFAP:Cre mice preserves the expression of the astrocyte GLT-1 glutamate transporter
Homogenates of the lumbar spinal cord from G85R flox /GFAP:Cre and G85R flox mice at different stages of disease were probed with anti-GLT-1 antibody (Fig. 5A and  B) . There was no statistical difference in the amount of GLT-1 antibody immunoreactivity before onset and at early stage of disease; however, there was a dramatic decrease in the GLT-1 at end stage in G85R flox mice compared with G85R flox /GFAP:Cre mice (P ¼ 0.002) and non-transgenic control mice (Fig. 5) .
DISCUSSION
Over 150 distinct mutations in SOD1 have been identified as a cause of FALS. Transgenic mice expressing a number of these MTSOD1s have provided the scientific community with a valuable tool for investigating the pathogenesis of FALS; however, an understanding of factors that are critical to MTSOD1-induced MN death remains unclear.
There is compelling evidence to support a non-cell autonomous degenerative disease process in MTSOD1-induced FALS. Evidence comes from a number of sources, especially Cre/loxP studies (5). Using Cre/loxP technology, the Cleveland laboratory found that knockdown of G37R in MNs of G37R transgenic mice delayed disease onset but not progression of disease, whereas knockdown in microglial cells and activated macrophages delayed the late phase of disease (with 250% increase) but not the onset or early disease (4, 12) . Our previously published results involving a knockdown of G85R in MNs and microglia of G85R transgenic mice were somewhat different: knockdown of G85R in spinal cord MNs and interneurons of the spinal cord and hind brain delayed disease onset (14.6%) and extended the early phase of disease (87.5%) but did not affect the late phase of the disease, whereas knockdown in microglia delayed the early (58.8%) and late phase (37.5%) of the disease but did not affect disease onset (6) . Additional experiments by the Cleveland laboratory found that G37R knockdown in astrocytes of G37R transgenic mice slowed the late phase of disease, but did not affect disease onset or the early phase of disease (11) . In contrast, the present studies found that G85R knockdown in astrocytes of G85R transgenic mice affected disease onset and early disease but not late disease. The early involvement of astrocytes has also been stressed in the case of G93A mice, in which upregulation of GFAP in the spinal cord was detected before disease onset (15) . The Cleveland laboratory noted that the effect of G37R astrocyte knockdown in G37R transgenic mice on the late phase of disease was similar to that seen following G37R knockdown in microglial cells (11) . In addition, the G37R knockdown in astrocytes was associated with a delay in the appearance and infiltration of activated microglial cells. These results suggested that astrocytes had an indirect effect on the disease because they augmented the pathogenic inflammatory response of microglia. Of note, we similarly found a decrease in microgliosis before onset and throughout disease following knockdown of G85R in astrocytes of G85R transgenic mice. Although we suspect that the decreased microgliosis plays a part in the amelioration of disease seen following G85R astrocyte knockdown, it seems unlikely that the effect on disease is primarily or completely caused by decreased microgliosis as the knockdown of G85R in astrocytes of G85R transgenic mice affected onset and early disease duration, whereas knockdown of G85R in activated microglia/ macrophages affected early and late disease but had no effect on onset (6) . The effect on disease that we saw following a G85R knockdown in astrocytes was actually more similar to that seen following G85R knockdown in MNs of G85R transgenic mice than in microglia (6) .
Why did the knockdown of G85R in astrocytes of G85R transgenic mice have a different effect on disease than the G37R knockdown in astrocytes of G37R transgenic mice? The different effect was not related to the knockdown itself as the GFAP:Cre mouse used in both studies was identical, with the same GFAP promoter driving Cre (14) . In addition, the extent of the knockdown was almost identical, at 80% in both studies. Of note, a previously published study of a different G85R transgenic mouse reported that astrocytes accumulated ubiquitin and SOD1 inclusions as early as MNs, with a prominent loss of the GLT-1 glutamate transporter (7). The latter findings prompted the authors to conjecture that G85R can directly lead to astrocyte damage, which plays a key role in MN degeneration. Similarly, the G85R transgenic mice used in the present study had a large number of SOD1 aggregates in astrocytes as well as a marked decrease in GLT-1 expression at the end stage of the disease, suggesting that impairment of glutamate reuptake into astrocytes leads to excitotoxicity and contributes to MN death. The accumulation of G85R MTSOD1 in aggregates in astrocytes might also lead to ER stress, which has been reported to be pathogenic in MNs in FALS (16) . G85R flox /GFAP:Cre mice had a preservation of GLT-1 expression and a dramatic decrease in aggregate formation in astrocytes and other cell types (e.g. in microglia, perhaps as a result of decreased microgliosis). The relative diminution in MTSOD1 aggregate formation, the preservation of GLT-1 expression and decreased microgliosis seen with the knockdown of G85R in astrocytes in G85R mice presumably all played a role in ameliorating the disease.
Of interest is the fact that G85R flox /GFAP:Cre mice died despite the knockdown of G85R in astrocytes and preservation of GLT-1 expression, indicating that the participation of astrocytes and diminished GLT-1 expression are not necessary for disease progression and death of the G85R mouse, and that other pathogenic forces are important. The incomplete role that astrocytes play in FALS pathogenesis is supported by other data that showed that expression of MTSOD1 exclusively in astrocytes is not sufficient to cause ALS (17), i.e. MTSOD1 expression in astrocytes must be accompanied by MTSOD1 expression in other cell types in order to cause disease. It is also of interest that G85R flox /GFAP:Cre mice died with a relatively small number of MTSOD1 aggregates, indicating that substantial accumulations of MTSOD1 are not necessary for disease progression and death in G85R mice.
The differing impact of astrocyte expression of G85R versus G37R on disease is presumably due to different properties of the MTSOD1s. For example, G85R is known to be more unstable than G37R with little, if any, evidence of intrasubunit disulfide bond formation (18) . Also of note, G85R has no SOD activity, whereas G37R has full activity. It is possible that in addition to its toxic effects, G37R has neuroprotective effects because its full enzymatic activity protects certain cell types from oxidative damage (reviewed in 1). As a result of this neuroprotective activity, G37R may not be as deleterious in the G37R mouse as a mutant with no dismutase activity, such as G85R; if this is the case, then a knockdown of G85R expression in astrocytes would have a more ameliorative effect on disease than a G37R knockdown in astrocytes. Of possible relevance to this issue is the surprising result that knockdown of G37R in Schwann cells of a transgenic mouse 'accelerated' FALS (19) , suggesting that G37R was more neuroprotective than neurotoxic in Schwann cells; another study provided some confirmation of the latter results by showing that crossing a transgenic mouse that expresses G93A (which has full dismutase activity) in all cells with a mouse that overexpresses G93A just in Schwann cells had no deleterious effect and modestly prolonged late disease duration (20) . Of note, there are a number of pathogenic mutant proteins responsible for neurodegenerative diseases that are thought to cause features of disease as a result of both gain and loss in function (21 -26) .
These studies demonstrate that non-MN neural cell types affect MTSOD1-induced FALS and that different cell types affect different stages of the disease. Our studies also emphasize the distinctive and varied ways by which different MTSOD1s can lead to MN death; it may be that the dismutase activity of a particular MTSOD1 is important in its influence on non-cell autonomous degeneration and disease. The effect of G85R astrocyte knockdown on onset as well as disease duration highlights the importance of this cell type in FALS.
MATERIALS AND METHODS
Mice and breeding
G85R
flox transgenic mice (6) were crossed with GFAP:Cre mice (14) to produce G85R flox /GFAP:Cre mice. Both mice were on a C57BL/6J background. The primers used for genotyping were: SOD1 forward, 5
.
Studies of human SOD1 expression
To determine the amount of knockdown of SOD1 that occurred following Cre excision in astrocytes, primary astrocytes obtained from four different embryos carrying the transgene(s) from two pregnant G85R flox mice and two pregnant G85R flox / GFAP:Cre mice were isolated, purified and cultured, as described previously (27) . qPCR of each separate culture was used to assess the level of mRNA knockdown and western immunoblotting was used to quantitate the decrease in SOD1 protein levels using previously published methods (6) . Astrocyte cultures were .95% pure as demonstrated by staining with anti-GFAP antibody.
Clinical assessment of phenotype
Mice were weighed every 2 days and clinically assessed as described previously with respect to onset, early disease phase and late disease phase (12) . In experiments monitoring disease parameters and survival, G85R flox /GFAP:Cre double transgenic mice were compared with their littermate G85R flox single transgenic mice.
Pathology and immunohistochemical evaluation
The pathology of the spinal cord and immunohistochemical staining were evaluated as described previously (6) . Briefly, the lumbar part of the spinal cord was dissected and embedded in paraffin for sectioning. Immunostaining was performed with the following antibodies: anti-GFAP (1:2000; Chemicon, Tamecula, CA, USA), anti-Iba1 (1:2000; Wako Chemicals USA, Richmond, VA, USA) and anti-SOD1 (28) (1:5000). The number of MNs in the lumbar spinal cord anterior horn was compared before onset, at early disease phase and end stage of the disease in G85R flox /GFAP:Cre double transgenic mice versus G85R flox single transgenic mice as described previously (29) . The number of anti-GFAP immunoreactive astrocytes and anti-Iba1-activated microglia/macrophages per square millimeter in the lumbar anterior horn were compared by using Image J software (NIH, Bethesda, MD, USA) on 15 -20 fields from four mice from each of the two groups in each phase of the disease. The number of anti-SOD1 immunoreactive inclusions was compared at end stage between the two groups by adjusting the Image J software to exclude very small immunoreactive material.
For double immunofluorescence studies, sections were blocked for 1 h with a blocking solution supplied with a Mouse-on-Mouse kit (Vector Laboratories, Burlingame, CA, USA) and then incubated with the following antibodies: rabbit anti-SOD1 (28) (1:1000) and either mouse anti-GFAP (1:500; Millipore) or mouse anti-Mac-2 (1:500; Credarlane, Burlington, NC, USA) followed by species-specific secondary antibodies conjugated to either FITC or Cy5 (1:200) (Jackson ImmunoResearch Labs, West Grove, PA, USA). Images were captured using a confocal laser scanning microscope (Olympus FluoView, Center Valley, PA, USA).
Studies of GLT-1 expression. The lumbar spinal cord was homogenized in 200 ml homogenizing buffer (20 mM Tris, pH 8.0, 150 mM NaCl, 1 mM EDTA, 0.5% Triton X-100, 0.5% sodium deoxycholate) that contained a protease inhibitor cocktail. About 10 mg of total protein was loaded on 10% sodium dodecyl sulfate (SDS) -polyacrylamide gels for western blot analysis, as described previously (30) . Western blots were probed with the anti-GLT-1 antibody (EAAT2, 1:1000, Santa Cruz Biotechnology, Santa Cruz, CA, USA) as well as anti-b-tubulin antibody. Homogenates of four G85R flox /GFAP:Cre mice and four G85R flox mice from each stage of disease (pre-onset, early phase and late phase) as well as four non-transgenic control mice were western-blotted. The intensity of the GLT-1 bands was adjusted to the same intensity of the b-tubulin band, and then the GLT-1 band intensity was compared with the non-transgenic GLT-1 for quantitation.
